title: Cytapheresis for the treatment of myeloperoxidase antineutrophil cytoplasmic autoantibody-associated vasculitis: a pilot study of 21 patients.
abstract: Twenty-one patients with myeloperoxidase-antineutrophil cytoplasmic autoantibody (MPO-ANCA)-associated vasculitis were treated using cytapheresis. Of these, 17 were treated for glomerulonephritis and four were treated for pulmonary hemorrhage. The overall survival rate was 85.7% with a follow-up duration of 24.0 +/- 13.8 months. In the 17 patients with MPO-ANCA-associated glomerulonephritis, pretreatment creatinine was 3.2 +/- 1.6 mg/dL, and renal function recovered in 76.5%. Pulmonary hemorrhage was ameliorated in all four patients. Abdominal pain occurred in three of the 21 patients but symptoms resolved soon after the cytapheresis procedure was completed. No other adverse effects occurred during cytapheresis. From these results, cytapheresis can be considered a safe and effective treatment for MPO-ANCA-associated vasculitis. As for the mechanism of its action, soluble tumor necrosis factor receptor 1 (sTNFR), sTNFR2 and interleukin 1 receptor antagonist were elevated soon after cytapheresis and those levels 2 h after the cytapheresis procedure were higher than before the procedure in some cases. These elevations might be related to the efficacy of cytapheresis.
authors.affiliation: Department of Nephrology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan. mhase@fujita-hu.ac.jp
authors.forename: Midori
authors.initials: M
authors.lastname: Hasegawa
authors.forename: Atsushi
authors.initials: A
authors.lastname: Ohashi
authors.forename: Nao
authors.initials: N
authors.lastname: Kabutan
authors.forename: Saori
authors.initials: S
authors.lastname: Hiramatsu
authors.forename: Masao
authors.initials: M
authors.lastname: Kato
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Murakami
authors.forename: Makoto
authors.initials: M
authors.lastname: Tomita
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Nabeshima
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Hiki
authors.forename: Satoshi
authors.initials: S
authors.lastname: Sugiyama
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000276:immunology*; D003404:Creatinine / Q000097:blood; D016238:Cytapheresis; D005260:Female; D006470:Hemorrhage / Q000209:etiology / Q000628:therapy; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000097:blood; D008171:Lung Diseases / Q000209:etiology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009195:Peroxidase / Q000276:immunology; D010865:Pilot Projects; D047888:Receptors, Tumor Necrosis Factor, Type I; D047889:Receptors, Tumor Necrosis Factor, Type II / Q000097:blood; D014657:Vasculitis / Q000150:complications / Q000276:immunology / Q000628:therapy*
chemical_list: D019268:Antibodies, Antineutrophil Cytoplasmic; D053590:Interleukin 1 Receptor Antagonist Protein; D047888:Receptors, Tumor Necrosis Factor, Type I; D047889:Receptors, Tumor Necrosis Factor, Type II; D003404:Creatinine; D009195:Peroxidase